At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 204 enrolled
Drug / intervention
EGb761 +2 moredrug
Likely dose
EGb761 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multicentre, Randomised, Double-blinded, Parallel Group, Placebo Controlled Clinical Study for Evaluating the Efficacy of EGb 761® (Tanakan®) (240mg) in the Recovery of Neurological Impairment Following Ischemic Stroke
In Brief
A Phase 3 clinical trial evaluating EGb761, Placebo, and 1 other intervention for Stroke, Acute and Neurological Impairment. Completed, enrolled 204 participants across 10 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate the effectiveness of Tanakan® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Acute, Neurological Impairment
CountriesCzechia, Poland, Romania, Russia
Collaborators--
Timeline
Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2003
First PostedJan 2006
Primary CompletionMar 2009
TodayJul 2026
First PostedJan 13, 2006
Enrollment StartFeb 1, 2003
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 20.5 years ago
Interventions
EGb761drug
EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.
Placebodrug
Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
Acetylsalicylic aciddrug
Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.